Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
PROSPAX |
RCV004818540 | SCV005061996 | likely pathogenic | Hereditary spastic paraplegia 7 | 2022-01-01 | criteria provided, single submitter | research | |
Fulgent Genetics, |
RCV004818540 | SCV005642499 | likely pathogenic | Hereditary spastic paraplegia 7 | 2024-06-01 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV004818540 | SCV005817403 | pathogenic | Hereditary spastic paraplegia 7 | 2024-11-19 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Glu112Aspfs*42) in the SPG7 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in SPG7 are known to be pathogenic (PMID: 21623769, 22964162). This variant is present in population databases (rs752830674, gnomAD 0.01%). This variant has not been reported in the literature in individuals affected with SPG7-related conditions. For these reasons, this variant has been classified as Pathogenic. |